# An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users

> **NCT06097676** · PHASE4 · COMPLETED · sponsor: **Arbor Pharmaceuticals, Inc.** · enrollment: 86 (actual)

## Conditions studied

- Abuse Potential

## Interventions

- **DRUG:** Placebo
- **DRUG:** Alprazolam 2 mg
- **DRUG:** Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg
- **DRUG:** Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg
- **DRUG:** Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg

## Key facts

- **NCT ID:** NCT06097676
- **Lead sponsor:** Arbor Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-28
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2024-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06097676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06097676, "An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06097676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*